STOCK TITAN

Quanterix Corp - QTRX STOCK NEWS

Welcome to our dedicated news page for Quanterix (Ticker: QTRX), a resource for investors and traders seeking the latest updates and insights on Quanterix.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Quanterix's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Quanterix's position in the market.

Rhea-AI Summary
Quanterix Corporation (NASDAQ: QTRX) will report financial results for Q3 2023 on November 6, 2023. A webcast and conference call will be held on November 7, 2023 at 8:30 a.m. E.T. Interested investors can pre-register for the conference call and access the live webcast from the Quanterix website. An archived webcast replay will be available on the website for one year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.59%
Tags
conferences earnings
-
Rhea-AI Summary
Lucent Diagnostics, a diagnostics brand of Quanterix Corporation, has announced the expansion of its LucentAD product line with the addition of a high accuracy p-Tau 217 blood test for Alzheimer’s disease. The test marks a major advance in the performance of blood biomarker tests for assessing amyloid pathology in individuals with memory complaints. The LucentAD p-Tau 217 test achieved an overall accuracy exceeding 90%, meeting the requirements set forth in the most recent NIA-AA Revised Criteria for Diagnosis and Staging of Alzheimer's Disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.83%
Tags
none
-
Rhea-AI Summary
Quanterix signs license agreement with Janssen to access p-Tau 217 antibodies for Alzheimer's Disease research and diagnostics. Quanterix will have worldwide rights to produce assay kits and launch a Laboratory Developed Test based on the antibodies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.36%
Tags
none
Rhea-AI Summary
Quanterix CEO to speak at Goldman Sachs Alzheimer’s Disease Day on October 3, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.93%
Tags
conferences
-
Rhea-AI Summary
Quanterix CEO to participate in fireside chat at Morgan Stanley conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.86%
Tags
conferences
-
Rhea-AI Summary
Quanterix Corporation appoints William P. Donnelly to its Board of Directors
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.15%
Tags
management
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.81%
Tags
management
-
Rhea-AI Summary
Quanterix Corporation reports Q2 2023 financial results, with total revenue of $31.0 million, a 32% increase YoY. GAAP gross margin improved to 61.7% from 37.1% in Q2 2022. Net loss was $6.1 million, an improvement from $24.9 million in Q2 2022. Cash and cash equivalents remained stable at $329.5 million. Quanterix expects full-year revenue to be in the range of $110 to $116 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.89%
Tags
-
Rhea-AI Summary
Quanterix Corporation (NASDAQ: QTRX) to Present at Canaccord Genuity 43rd Annual Growth Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.68%
Tags
conferences
Quanterix Corp

Nasdaq:QTRX

QTRX Rankings

QTRX Stock Data

699.23M
32.52M
8.72%
85.23%
2.63%
Testing Laboratories
Professional, Scientific, and Technical Services
Link
United States
Billerica

About QTRX

quanterix offers an ultra-sensitive diagnostic platform capable of measuring individual proteins at concentrations 1000 times lower than the best immunoassays available today. the single molecule array (simoa™) technology at the heart of the platform enables the detection and quantification of biomarkers previously difficult or impossible to measure, opening up new applications to address significant unmet needs in life science research, in-vitro diagnostics, companion diagnostics, blood screening, and more. quanterix is a venture capital backed company and the exclusive licensee of a broad intellectual property portfolio initially developed at tufts university by dr. david walt, scientific founder of quanterix and illumina (nasdaq: ilmn).